 |
BioWorld-International-2008-07-23
Antisoma, Novartis Expand ASA404 into Lung Cancer
Antisoma, Novartis Expand ASA404 into Lung Cancer
LONDON - Antisoma plc said its partner Novartis AG will take ASA404, a vascular disrupting agent, into a second pivotal Phase III trial in the second-line treatment of non-small-cell lung cancer, a move that will open up a bigger market if the trial is positive. (BioWorld International)
Cytheris Receives €1.5M Loan for HCV Clinical Development
No Abstract
BioWorld International Correspondent
PARIS - Cytheris SA has received a €1.5 million (US$2.3 million) interest-free loan from OSEO, France's national industrial innovation agency, to support its continuing clinical development program in hepatitis C (HCV).
The funds will enable Paris-based Cytheris to push ahead with the development of its lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth factor for immune T-cell recovery and enhancement.